

September 19, 2014



## Tonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference

NEW YORK, Sept. 19, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 21<sup>st</sup> Annual BioCentury NewsMakers in the Biotech Industry conference on Friday, September 26, 2014 at 8:30 am ET in New York City.

The presentation will be webcast live and may be accessed in the Events tab of the Investor Relations page of Tonix's website at [www.tonixpharma.com](http://www.tonixpharma.com). The webcast will be archived for 60 days and made available through Tonix's website.

Tonix Pharmaceuticals develops innovative prescription medicines for patients who suffer from common central nervous system disorders. The company's clinical candidates target disorders for which current treatment options are unsatisfactory and healthcare utilization is considerable, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. To learn more, please visit [www.tonixpharma.com](http://www.tonixpharma.com).

### **Forward-Looking Statements**

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 28, 2014 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.*

CONTACT: Tonix Pharmaceuticals Holding Corp.  
Leland Gershell  
Chief Financial Officer  
(212) 980-9155 x104

leland.gershell@tonixpharma.com

Public Relations:  
Dian Griesel Int'l.  
Susan Forman / Laura Radocaj  
(212) 825-3210  
sforman@dgicomm.com  
lradocaj@dgicomm.com

**Source: Tonix Pharmaceuticals Holding Corp.**